mRNA Polydispersity Analysis Service
In the rapidly evolving landscape of therapeutic nucleic acid development, the molecular homogeneity of messenger RNA (mRNA) is a cornerstone of therapeutic safety and efficacy. mRNA polydispersity, a measure of the distribution of molecular mass and size within a sample, serves as a critical indicator of product quality. For mRNA-based vaccines, high polydispersity often signals the presence of degradation products, incomplete transcripts, or undesirable molecular aggregates, all of which can compromise translational efficiency and potentially trigger adverse immune responses.
At CD BioGlyco, we specialize in high-resolution mRNA polydispersity analysis services. By accurately quantifying the polydispersity index (PDI) and characterizing the size distribution of mRNA molecules, we empower researchers to validate their manufacturing processes and ensure that their drug substances meet the stringent requirements of regulatory bodies. Our services are integrated into our broader mRNA structural characterization suite, providing the deep molecular insights necessary to transition from laboratory-scale synthesis to commercial-grade vaccine production.
As a pivotal component of the mRNA-based vaccine development platform, our analysis services focus on the exhaustive mRNA structural characterization required for therapeutic success. Our scope includes:
Our experts collaborate with you to define the specific requirements of your mRNA construct, including expected molecular weight and potential impurities, to tailor the optimal analytical strategy.
Samples are prepared under nuclease-free conditions. We offer both denaturing and non-denaturing conditions to assess mRNA in its primary sequence form or its complex tertiary folding state.
The sample undergoes analysis through our integrated SEC-MALS and DLS systems. If required, CGE is performed in parallel to provide an orthogonal verification of molecular length and integrity.
Using sophisticated software, our bioinformaticians process raw light scattering and refractive index data to calculate absolute molar mass, Rg, Rh, and the resulting PDI.
Every data set is reviewed against internal standards and client-specified benchmarks to ensure that the reported polydispersity values are accurate and representative of the batch.
We deliver a detailed analytical report featuring all chromatographic profiles, distribution plots, and statistical summaries. A post-analysis debriefing is available to discuss the implications of the results for your vaccine development.
Vaccine Candidate Screening
Rapidly assess the homogeneity of different mRNA sequences during early-stage development to select the most stable and uniform candidates for further preclinical evaluation.
Manufacturing Process Optimization
Use polydispersity as a key performance indicator (KPI) to optimize in vitro transcription (IVT) parameters, ensuring consistent batch-to-batch production and minimal byproduct formation.
Documentation Support
Generate high-quality, absolute characterization data required for project research to satisfy safety and quality standards.
LNP Formulation Stability
Evaluate how the mRNA structure and polydispersity are maintained during and after the encapsulation process, ensuring the final drug product remains therapeutically active.
Absolute Characterization Excellence
Our SEC-MALS platform provides first-principles measurements of molecular weight, eliminating the inaccuracies associated with standard-based calibration for complex, non-globular mRNA molecules.
High-Resolution Sensitivity
We utilize state-of-the-art detectors capable of identifying trace amounts of high-molecular-weight aggregates or low-molecular-weight fragments that could otherwise go undetected in routine assays.
Tailored Scientific Expertise
With years of experience in therapeutic nucleic acid development, our specialists provide more than just data; we provide deep insights into the structural biology of your mRNA.
Orthogonal Method Verification
By combining light scattering, chromatography, and electrophoresis, we provide a holistic view of polydispersity that cross-validates results for maximum confidence in your data.
The SEC-MALS data provided by CD BioGlyco was instrumental in our recent study. Their ability to characterize the absolute molecular weight and polydispersity of our 4kb mRNA transcript gave us the confidence we needed to move forward. The technical support was exceptional.
— Dr. S.K., Leading Biotech
We were struggling with inconsistent batch quality until we utilized CD BioGlyco's polydispersity analysis. Their insight into our aggregation issues allowed us to refine our IVT process and significantly increase our yield of full-length mRNA.
— B.G., European Vaccine Institute
Fast, professional, and scientifically rigorous. The detailed reports from CD BioGlyco have become a standard part of our quality control workflow for all our therapeutic nucleic acid projects.
— B.E., Pharmaceutical Startup
CD BioGlyco is committed to advancing the field of mRNA-based vaccine development by providing the most precise mRNA polydispersity analysis service available. By ensuring the molecular homogeneity of your mRNA through advanced mRNA structural characterization, we help you mitigate risks and accelerate the delivery of safe, effective therapies to the global market. Please feel free to contact us for detailed information on our services or to request a customized quote for your project.
